Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06361836 · ClinicalTrials.gov registry record · Phase 1
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
A Phase 1 study of Hidradenitis Suppurativa, sponsored by Sonoma Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 6
- Study locations
NCT06361836: Active Phase 1 study of Hidradenitis Suppurativa, sponsored by Sonoma Biotherapeutics.
NCT06361836 is a Phase 1 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Sonoma Biotherapeutics. The registered enrollment target is 24 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06361836, a Phase 1 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Sonoma Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
Conditions Studied
Interventions
- BIOLOGICAL SBT777101
Study Locations (6)
Massachusetts
- Brigham and Women's Hospital - Boston
Minnesota
- University of Minnesota - Minneapolis
Missouri
- SLUCare Academic Pavillion - St Louis
New York
- Columbia University Irving Medical Center - New York
North Carolina
- Duke University - Durham
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-10-09 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What the registry record for NCT06361836 still lists
NCT06361836 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which SBT777101 is the first listed.
NCT06361836 lists 6 locations in 6 states (Massachusetts, Minnesota, Missouri).
Frequently Asked Questions
What is clinical trial NCT06361836 about?
NCT06361836 is a clinical study titled "Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa". This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
What is the current status of trial NCT06361836?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-10-09. Estimated completion is 2026-11.
What conditions does trial NCT06361836 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06361836?
The interventions under investigation include: SBT777101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06361836?
This trial is sponsored by Sonoma Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06361836 being conducted?
This trial has 6 study locations across Massachusetts, Minnesota, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06361836's enrollment target sits among peer trials
24 38th of 52 higher than 13 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI